Safety and efficacy of galcanezumab in Taiwanese patients: a post-hoc analysis of phase 3 studies in episodic and chronic migraine

References

• Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013;33(9):629–808.
   PubMed Web of Science ®Google Scholar
• Chen P-K, Wang S-J. Non-headache symptoms in migraine patients. F1000Res. 2018;7:188–188.
   PubMedGoogle Scholar
• Yang CP, Wang SJ. Sleep in patients with chronic migraine. Curr Pain Headache Rep. 2017;21(9):39.
   PubMed Web of Science ®Google Scholar
• Wang S-J, Chen P-K, Fuh J-L. Comorbidities of migraine. Front Neurol. 2010;1:16–16.
   PubMedGoogle Scholar
• Steiner TJ, Stovner LJ, Vos T, et al. Migraine is first cause of disability in under 50s: will health politicians now take notice? J Headache Pain. 2018;19(1):17–17.
   PubMed Web of Science ®Google Scholar
• Woldeamanuel YW, Cowan RP. Migraine affects 1 in 10 people worldwide featuring recent rise: a systematic review and meta-analysis of community-based studies involving 6 million participants. J Neurol Sci. 2017;372:307–315.
   PubMed Web of Science ®Google Scholar
• Vetvik KG, MacGregor EA. Sex differences in the epidemiology, clinical features, and pathophysiology of migraine. Lancet Neurol. 2017;16(1):76–87.
   PubMed Web of Science ®Google Scholar
• Peng KP, Wang SJ. Epidemiology of headache disorders in the Asia-Pacific region. Headache. 2014;54(4):610–618.
   PubMed Web of Science ®Google Scholar
• Wang SJ, Fuh JL, Young YH, et al. Prevalence of migraine in Taipei, Taiwan: a population-based survey. Cephalalgia. 2000;20(6):566–572.
   PubMed Web of Science ®Google Scholar
• Wang SJ, Wang PJ, Fuh JL, et al. Comparisons of disability, quality of life, and resource use between chronic and episodic migraineurs: a clinic-based study in Taiwan. Cephalalgia. 2013;33(3):171–181.
   PubMed Web of Science ®Google Scholar
• Hung PH, Fuh JL, Wang SJ. Validity, reliability and application of the Taiwan version of the migraine disability assessment questionnaire. Journal of the Formosan Medical Association = Taiwan yi Zhi. 2006;105(7):563–568.
   PubMed Web of Science ®Google Scholar
• Chen YC, Tang CH, Ng K, et al. Comorbidity profiles of chronic migraine sufferers in a national database in Taiwan. J Headache Pain. 2012;13(4):311–319.
   PubMed Web of Science ®Google Scholar
• Fuh JL, Wang SJ, Lu SR. Impact of migraine on the employed labor force in Taiwan. J Chin Med Assoc. 2008;71(2):74–78.
   PubMed Web of Science ®Google Scholar
• Silberstein SD. Preventive migraine treatment. Continuum. 2015;21(4 Headache):973–989.
   PubMedGoogle Scholar
• Wang SJ, Chung CS, Chankrachang S, et al. Migraine disability awareness campaign in Asia: migraine assessment for prophylaxis. Headache. 2008;48(9):1356–1365.
   PubMed Web of Science ®Google Scholar
• Huang T-C, Lai T-H, Treatment Guideline Subcommittee of Taiwan Headache Society Taiwan Headache Society. Medical treatment guidelines for preventive treatment of migraine. Acta Neurol Taiwan. 2017;26(1):33–53.
   PubMedGoogle Scholar
• Blumenfeld AM, Bloudek LM, Becker WJ, et al. Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II). Headache. 2013;53(4):644–655.
   PubMed Web of Science ®Google Scholar
• Berger A, Bloudek LM, Varon SF, et al. Adherence with migraine prophylaxis in clinical practice. Pain Pract. 2012;12(7):541–549.
   PubMed Web of Science ®Google Scholar
• Stauffer VL, Dodick DW, Zhang Q, et al. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol. 2018;75(9):1080–1088.
   PubMed Web of Science ®Google Scholar
• Skljarevski V, Matharu M, Millen BA, et al. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia. 2018;38(8):1442–1454.
   PubMed Web of Science ®Google Scholar
• Detke HC, Goadsby PJ, Wang S, et al. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018;91(24):e2211–e2221.
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Stauffer VL, Day KA, et al. Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2). J Headache Pain. 2019;20(1):118.
   PubMed Web of Science ®Google Scholar
• Yang Y, Wang Z, Gao B, et al. Different doses of galcanezumab versus placebo in patients with migraine and cluster headache: a meta-analysis of randomized controlled trials. J Headache Pain. 2020;21(1):14.
   PubMed Web of Science ®Google Scholar
• Raffaelli B, Mussetto V, Israel H, et al. Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination. J Headache Pain. 2019;20(1):66.
   PubMedGoogle Scholar
• Forderreuther S, Zhang Q, Stauffer VL, et al. Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies. J Headache Pain. 2018;19(1):121.
   PubMedGoogle Scholar
• Durham PL. Calcitonin gene-related peptide (CGRP) and migraine. Headache. 2006;46(Suppl 1):S3–S8.
   PubMedGoogle Scholar
• Ho TW, Edvinsson L, Goadsby PJ. CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol. 2010;6(10):573–582.
   PubMed Web of Science ®Google Scholar
• Lassen LH, Haderslev PA, Jacobsen VB, et al. CGRP may play a causative role in migraine. Cephalalgia. 2002;22(1):54–61.
   PubMed Web of Science ®Google Scholar
• Giamberardino MA, Affaitati G, Curto M, et al. Anti-CGRP monoclonal antibodies in migraine: current perspectives. Intern Emerg Med. 2016;11(8):1045–1057.
   PubMed Web of Science ®Google Scholar
• Ong JJY, Wei DY, Goadsby PJ. Recent Advances in pharmacotherapy for migraine prevention: from pathophysiology to new drugs. Drugs. 2018;78(4):411–437.
   PubMed Web of Science ®Google Scholar
• Sacco S, Bendtsen L, Ashina M, et al. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain. 2019;20(1):6.
   PubMed Web of Science ®Google Scholar
• Lamb YN. Galcanezumab: first global approval. Drugs. 2018;78(16):1769–1775.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761063.
   Google Scholar
• European Medicines Agency. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/emgality.
   Google Scholar
• Detke H, Pozo-Rosich P, Reuter U, et al. One-year treatment with galcanezumab in patients with chronic migraine: results from the open-label phase of the REGAIN Study (P2.10-010). Neurology. 2019;92(15 Supplement):P2.10–010.
   Google Scholar
• Wu T-Y, Majeed A, Kuo KN. An overview of the healthcare system in Taiwan. London J Prim Care. 2010;3(2):115–119.
   PubMedGoogle Scholar